Download PDF
Thromb Haemost 2019; 119(07): 1048-1057
DOI: 10.1055/s-0039-1687875
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Evaluating the Effects of Fibrinogen αC Mutations on the Ability of Factor XIII to Crosslink the Reactive αC Glutamines (Q237, Q328, Q366)

Kelly Njine Mouapi
1   Chemistry Department, University of Louisville, Louisville, Kentucky, United States
,
Lucille J. Wagner
1   Chemistry Department, University of Louisville, Louisville, Kentucky, United States
,
Chad A. Stephens
1   Chemistry Department, University of Louisville, Louisville, Kentucky, United States
,
Mohammed M. Hindi
1   Chemistry Department, University of Louisville, Louisville, Kentucky, United States
,
Daniel W. Wilkey
2   Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, Kentucky, United States
,
Michael L. Merchant
2   Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, Kentucky, United States
,
Muriel C. Maurer
1   Chemistry Department, University of Louisville, Louisville, Kentucky, United States
› Author Affiliations Funding This research project was funded by National Institutes of Health grant: NIH R15 HL120068.
Further Information

Publication History

30 September 2018

06 March 2019

Publication Date:
05 May 2019 (online)

    Permissions and Reprints

Abstract

Fibrinogen (Fbg) levels and extent of fibrin polymerization have been associated with various pathological conditions such as cardiovascular disease, arteriosclerosis, and coagulation disorders. Activated factor XIII (FXIIIa) introduces γ-glutamyl-ε-lysinyl isopeptide bonds between reactive glutamines and lysines in the fibrin network to form a blood clot resistant to fibrinolysis. FXIIIa crosslinks the γ-chains and at multiple sites in the αC region of Fbg. Fbg αC contains a FXIII binding site involving αC (389–402) that is located near three glutamines whose reactivities rank Q237 >> Q366 ≈ Q328. Mass spectrometry and two-dimensional heteronuclear single-quantum correlation nuclear magnetic resonance assays were used to probe the anchoring role that αC E396 may play in controlling FXIII function and characterize the effects of Q237 on the reactivities of Q328 and Q366. Studies with αC (233–425) revealed that the E396A mutation does not prevent the transglutaminase function of FXIII A2 or A2B2. Other residues must play a compensatory role in targeting FXIII to αC. Unlike full Fbg, Fbg αC (233–425) did not promote thrombin cleavage of FXIII, an event contributing to activation. With the αC (233–425) E396A mutant, Q237 exhibited slower reactivities compared with αC wild-type (WT) consistent with difficulties in directing this N-terminal segment toward an anchored FXIII interacting at a weaker binding region. Q328 and Q366 became less reactive when Q237 was replaced with inactive N237. Q237 crosslinking is proposed to promote targeting of Q328 and Q366 to the FXIII active site. FXIII thus uses Fbg αC anchoring sites and distinct Q environments to regulate substrate specificity.

Keywords

fibrinogen αC - factor XIII - coagulation - mass spectrometry - nuclear magnetic resonance

Authors' Contributions

K.N.M., D.W.D., M.L.M., and M.C.M. designed the research. K.N.M., L.J.W., C.A.S., M.M.H., and D.W.D. performed the experiments and analyzed the data. K.N.M., M.L.M., and M.C.M. critically evaluated the results and wrote the manuscript. All authors approved the final manuscript and figures.


Supplementary Material

 

  • References

  • 1 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121 (10) 1712-1719
    CrossrefPubMedGoogle Scholar
  • 2 Ariëns RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 01) 294-305
    CrossrefPubMedGoogle Scholar
  • 3 Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin?. Semin Thromb Hemost 2016; 42 (04) 333-343
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (08) 1894-1904
    CrossrefPubMedGoogle Scholar
  • 5 Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299
    CrossrefPubMedGoogle Scholar
  • 6 Yang Z, Mochalkin I, Veerapandian L, Riley M, Doolittle RF. Crystal structure of native chicken fibrinogen at 5.5-A resolution. Proc Natl Acad Sci U S A 2000; 97 (08) 3907-3912
    CrossrefPubMedGoogle Scholar
  • 7 Standeven KF, Ariëns RA, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005; 19 (05) 275-288
    CrossrefPubMedGoogle Scholar
  • 8 Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (03) 931-972
    CrossrefPubMedGoogle Scholar
  • 9 Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129 (03) 382-387
    CrossrefPubMedGoogle Scholar
  • 10 Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond) 2013; 124 (03) 123-137
    CrossrefPubMedGoogle Scholar
  • 11 Standeven KF, Carter AM, Grant PJ. , et al. Functional analysis of fibrin gamma-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110 (03) 902-907
    PubMedGoogle Scholar
  • 12 Cottrell BA, Strong DD, Watt KW, Doolittle RF. Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979; 18 (24) 5405-5410
    CrossrefPubMedGoogle Scholar
  • 13 Chen R, Doolittle RF. Cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10 (24) 4487-4491
    PubMedGoogle Scholar
  • 14 Byrnes JR, Wilson C, Boutelle AM. , et al. The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits. Blood 2016; 128 (15) 1969-1978
    PubMedGoogle Scholar
  • 15 Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275 (48) 37382-37389
    CrossrefPubMedGoogle Scholar
  • 16 Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. Biochemistry 2010; 49 (35) 7643-7651
    CrossrefPubMedGoogle Scholar
  • 17 Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariëns RA. Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111 (05) 842-850
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Protopopova AD, Barinov NA, Zavyalova EG, Kopylov AM, Sergienko VI, Klinov DV. Visualization of fibrinogen αC regions and their arrangement during fibrin network formation by high-resolution AFM. J Thromb Haemost 2015; 13 (04) 570-579
    CrossrefPubMedGoogle Scholar
  • 19 Protopopova AD, Litvinov RI, Galanakis DK. , et al. Morphometric characterization of fibrinogen's αC regions and their role in fibrin self-assembly and molecular organization. Nanoscale 2017; 9 (36) 13707-13716
    CrossrefPubMedGoogle Scholar
  • 20 Byrnes JR, Duval C, Wang Y. , et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126 (16) 1940-1948
    PubMedGoogle Scholar
  • 21 Aleman MM, Byrnes JR, Wang JG. , et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124 (08) 3590-3600
    CrossrefPubMedGoogle Scholar
  • 22 Credo RB, Curtis CG, Lorand L. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. Biochemistry 1981; 20 (13) 3770-3778
    CrossrefPubMedGoogle Scholar
  • 23 Procyk R, Bishop PD, Kudryk B. Fibrin--recombinant human factor XIII a-subunit association. Thromb Res 1993; 71 (02) 127-138
    CrossrefPubMedGoogle Scholar
  • 24 Smith KA, Adamson PJ, Pease RJ. , et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood 2011; 117 (12) 3460-3468
    CrossrefPubMedGoogle Scholar
  • 25 Smith KA, Pease RJ, Avery CA. , et al. The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood 2013; 121 (11) 2117-2126
    CrossrefPubMedGoogle Scholar
  • 26 Doolittle RF, Cassman KG, Cottrell BA, Friezner SJ. Amino acid sequence studies on the alpha chain of human fibrinogen. Isolation and characterization of two linked alpha-chained cyanogen bromide fragments from fully cross-linked fibrin. Biochemistry 1977; 16 (08) 1715-1719
    CrossrefPubMedGoogle Scholar
  • 27 Kárpáti L, Penke B, Katona E, Balogh I, Vámosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46 (12) 1946-1955
    CrossrefPubMedGoogle Scholar
  • 28 Cleary DB, Maurer MC. Characterizing the specificity of activated factor XIII for glutamine-containing substrate peptides. Biochim Biophys Acta 2006; 1764 (07) 1207-1217
    CrossrefPubMedGoogle Scholar
  • 29 Mouapi KN, Bell JD, Smith KA, Ariëns RA, Philippou H, Maurer MC. Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII. Blood 2016; 127 (18) 2241-2248
    CrossrefPubMedGoogle Scholar
  • 30 Matsuka YV, Medved LV, Migliorini MM, Ingham KC. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry 1996; 35 (18) 5810-5816
    CrossrefPubMedGoogle Scholar
  • 31 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248 (04) 1395-1407
    CrossrefPubMedGoogle Scholar
  • 32 Wang W. Identification of respective lysine donor and glutamine acceptor sites involved in factor XIIIa-catalyzed fibrin α chain cross-linking. J Biol Chem 2011; 286 (52) 44952-44964
    CrossrefPubMedGoogle Scholar
  • 33 Katona E, Haramura G, Kárpáti L, Fachet J, Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000; 83 (02) 268-273
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Schilling B, Rardin MJ, MacLean BX. , et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics 2012; 11 (05) 202-214
    CrossrefPubMedGoogle Scholar
  • 35 Doiphode PG, Malovichko MV, Mouapi KN, Maurer MC. Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. Anal Biochem 2014; 457: 74-84
    CrossrefPubMedGoogle Scholar
  • 36 Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98 (03) 632-639
    CrossrefPubMedGoogle Scholar
  • 37 Park R, Doh HJ, An SS, Choi JR, Chung KH, Song KS. A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood 2006; 108 (06) 1919-1924
    PubMedGoogle Scholar
  • 38 Hethershaw EL, Cilia La Corte AL, Duval C. , et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12 (02) 197-205
    CrossrefPubMedGoogle Scholar
  • 39 Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12 (10) 1687-1696
    CrossrefPubMedGoogle Scholar
  • 40 Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77 (05) 2813-2826
    CrossrefPubMedGoogle Scholar
  • 41 Helms CC, Ariëns RA, Uitte de Willige S, Standeven KF, Guthold M. α-α Cross-links increase fibrin fiber elasticity and stiffness. Biophys J 2012; 102 (01) 168-175
    CrossrefPubMedGoogle Scholar
  • 42 Kollman JM, Pandi L, Sawaya MR, Riley M, Doolittle RF. Crystal structure of human fibrinogen. Biochemistry 2009; 48 (18) 3877-3886
    CrossrefPubMedGoogle Scholar
  • 43 Tsurupa G, Tsonev L, Medved L. Structural organization of the fibrin(ogen) alpha C-domain. Biochemistry 2002; 41 (20) 6449-6459
    CrossrefPubMedGoogle Scholar
  • 44 Souri M, Osaki T, Ichinose A. The non-catalytic B subunit of coagulation factor XIII accelerates fibrin cross-linking. J Biol Chem 2015; 290 (19) 12027-12039
    CrossrefPubMedGoogle Scholar
  • 45 Byrnes JR, Wolberg AS. Newly-recognized roles of factor XIII in thrombosis. Semin Thromb Hemost 2016; 42 (04) 445-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991; 30 (04) 934-941
    CrossrefPubMedGoogle Scholar
  • 47 Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem 2000; 275 (52) 40671-40678
    CrossrefPubMedGoogle Scholar
  • 48 Ye J, Liu LW, Esmon CT, Johnson AE. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J Biol Chem 1992; 267 (16) 11023-11028
    CrossrefPubMedGoogle Scholar